| Literature DB >> 24123491 |
Paolo Fusar-Poli1, Joaquim Radua, Marianna Frascarelli, Andrea Mechelli, Stefan Borgwardt, Fabio Di Fabio, Massimo Biondi, John P A Ioannidis, Sean P David.
Abstract
OBJECTIVES: To evaluate whether biases may influence the findings of whole-brain structural imaging literature.Entities:
Keywords: VBM; bias; dementia; neuroimaging; psychosis; structural
Mesh:
Year: 2013 PMID: 24123491 PMCID: PMC6869352 DOI: 10.1002/hbm.22384
Source DB: PubMed Journal: Hum Brain Mapp ISSN: 1065-9471 Impact factor: 5.038
Figure 1Expected relationship between sample size and number of abnormalities detected by whole‐brain structural neuroimaging techniques.
Footnote: The number of abnormalities correctly detected as abnormal (P < 0.05) in a simulated study with that sample size is shown with solid lines. The number falsely detected abnormalities is shown with dotted lines. In all simulations, brain was composed of 5,000 independent parts, of which 95% were normal and 5% were abnormal.
Figure 2Relationship between sample size and number of clusters in simulated VBM data.
Figure 3PRISMA Flow chart of literature search.
List of articles included in the present meta‐meta‐analysis. Each meta‐analysis (contrast) used for each included study is detailed in the specific column
| Author | Year | Statistical threshold | Condition | Contrast | Sample | Number of foci |
|---|---|---|---|---|---|---|
| Yang | 2012 (Yang et al., 2012) |
| Semantic dementia | SD vs. HC | 235 | 10 |
| Bora | 2010 (Bora et al., 2010) |
| Bipolar disorder | BD vs. HC | 1430 | 3 |
| FE BD vs. HC | 197 | 1 | ||||
| Bora | 2011 (Bora et al., 2011) |
| Schizophrenia | SCZ vs. HC | 4087 | 5 |
| FEP vs. HC | 874 | 2 | ||||
| FEP vs. CHR SCZ | 4087 | 3 | ||||
| Bora | 2012 (Bora et al., 2012) |
| Depressive disorder | FE DEP vs. HC | 292 | 1 |
| ME DEP vs. HC | 1631 | 2 | ||||
| FE DEP vs. ME DEP | 1923 | 1 | ||||
| CO ANX vs. HC | 1117 | 1 | ||||
| NO CO ANX vs. HC | 558 | 2 | ||||
| C DEP vs. HC | 1414 | 1 | ||||
| Chen | 2010 (Chen and Ma 2010) |
| Amyotrophic lateral sclerosis | ALS vs. HC | 165 | 1 |
| Fusar‐Poli | 2011 (Fusar‐Poli et al., 2011a) |
| Psychosis risk | Clinical HR vs. HC | 516 | 5 |
| HR NoTransition vs. HR Transition | 165 | 2 | ||||
| Genetic HR vs. HC | 952 | 3 | ||||
| Genetic HR vs. Clinical HR | 1468 | 5 | ||||
| HR vs. SCZ | 754 | 5 | ||||
| Fusar‐Poli | 2011 (Fusar‐Poli et al., 2011b) |
| Psychosis onset | FEP vs. HC | 413 | 3 |
| FEP vs. HR | 865 | 4 | ||||
| Lai | 2011 (Lai 2011) |
| Panic disorder | PD vs. HC | 226 | 2 |
| Li | 2012 (Palaniyappan et al., 2012) |
| Epilepsy | RTLE vs. HC | 300 | 7 |
| LTLE vs. HC | 433 | 11 | ||||
| Modinos | 2012 (Modinos et al., 2012) |
| Auditory verbal hallucinations | AVHs Severe vs. AVHs Non severe | 259 | 6 |
| SCZ AVHs vs. SCZ No AVHs | 266 | 0 | ||||
| Nakao | 2011 (Nakao et al., 2011) |
| ADHD | ADHD vs. HC | 722 | 2 |
| Nickl‐Jockschat | 2012 (Nickl‐Jockschat et al., 2012b) |
| Mild cognitive impairment | MCI vs. HC | 1726 | 3 |
| Amnestic MCI vs. HC | 1659 | 5 | ||||
| Pan | 2012 (Pan et al., 2012a) | n.a. | Parkinson's disease | PKD vs. HC | 873 | 1 |
| Pan | 2012 (Pan,, 2012b) |
| BV‐Fronto temporal dementia | BV‐FTD vs. HC | 534 | 1 |
| Radua | 2010 (Radua et al. |
| Anxiety disorders | OCD vs. HC | 836 | 4 |
| OAD vs. HC | 483 | 3 | ||||
| OCD vs. OAD | 1376 | 3 | ||||
| Richlan | 2012 (Richlan et al., 2012) |
| Dyslexia | DYL vs. HC | 266 | 5 |
| Schroeter | 2009 (Schroeter et al., 2009) |
| Alzheimer's disease | AD vs. HC | 421 | 6 |
| Via | 2011 (Via et al., 2011) |
| Autism Spectrum Disorder | ASD vs. HC | 967 | 5 |
| AUT vs. ASP | 905 | 0 | ||||
| CHI ASD vs. ADU ASD | 967 | 1 | ||||
| Zheng | 2012 (Zheng et al., 2012) |
| Focal dystonia | DYT vs. HC | 446 | 5 |
| Yu | 2010 (Yu et al., 2010) |
| Bipolar disorder and schizophrenia | BD vs. SCZ | 2617 | 23 |
| Ferreira | 2011 (Ferreira et al., 2011) |
| Mild cognitive impairment | MCI conv vs. MCI st | 479 | 1 |
| Yu | 2011 (Yu et al., 2011) |
| Autism spectrum disorder | AUT vs. HC | 343 | 24 |
| ASP vs. HC | 374 | 13 | ||||
| Frodl | 2012 (Frodl and Skokauskas 2012) |
| ADHD | CHI ADHD vs. HC | 348 | 2 |
| ADU ADHD vs. HC | 260 | 2 | ||||
| Rotge | 2010 (Rotge et al., 2010) |
| OCD | CHI OCD vs. HC | 149 | 16 |
| ADU OCD vs. HC | 512 | 13 |
AD = Alzheimer's disease; ADHD = attention deficit‐hyperactivity disorder; ADU = adults; ALS = amyotrophic lateral sclerosis; ASP = Asperger disorder; ASP = autism spectrum disorders; AUT = autism; AVHs = auditory verbal hallucinations; BD = bipolar disorder; BV‐FTD = behavioral variant fronto‐temporal dementia; C = currently; CHI = children; CHR = chronic; CO ANX = comorbid anxiety; conv = converters; DEP = depressive disorder; DYL = dyslexia; DYT = dystonia; FDR = false discovery rate; FE = first episode; FEP = first episode psychosis; HC = healthy controls; HR = high risk; LTLE = left temporal lobe epilepsy; MCI = mild cognitive impairment; n.a. = non available; OAD = other anxiety disorders; OCD = obsessive‐compulsive disorder; PD = panic disorder; PKD = Parkinson's disease; RTLE = right temporal lobe epilepsy; SCZ = schizophrenia; SD = semantic dementia; st = stable.
Number of participants and reported foci in the VBM studies (a) and meta‐analyses (b) included in the present study
| Number of participants | Number of foci | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Min | Q1 | Median | Q3 | Max | Min | Q1 | Median | Q3 | Max | |
| (a) All studies | 12 | 33 | 47 | 72 | 545 | 0 | 2 | 6 | 11 | 105 |
| Studies of psychiatric disorders | 12 | 34 | 52 | 79 | 425 | 0 | 2 | 5 | 10 | 58 |
| Studies of neurological disorders | 13 | 30 | 41 | 66 | 545 | 0 | 3 | 7 | 13 | 105 |
| Studies of non‐affective psychosis | 12 | 37 | 62 | 87 | 425 | 0 | 2 | 6 | 12 | 38 |
| Studies of dementia | 13 | 29 | 40 | 63 | 545 | 0 | 3 | 7 | 12 | 105 |
| Studies of neurological diseases other than dementia | 16 | 31 | 41 | 66 | 134 | 0 | 2 | 7 | 14 | 48 |
| Studies of anxiety disorders | 20 | 34 | 39 | 51 | 144 | 0 | 1 | 3 | 7 | 19 |
| Studies of autism | 20 | 30 | 33 | 65 | 188 | 0 | 1 | 5 | 9 | 58 |
| Studies of bipolar disorder | 26 | 48 | 68 | 84 | 132 | 0 | 2 | 6 | 17 | 33 |
| Studies of depressive disorders | 27 | 36 | 60 | 90 | 328 | 0 | 2 | 6 | 11 | 24 |
| Studies of ADHD | 24 | 31 | 40 | 57 | 128 | 0 | 0 | 4 | 8 | 17 |
| Studies published up to 2008 | 12 | 30 | 42 | 72 | 425 | 0 | 3 | 7 | 11 | 105 |
| Studies published after 2008 | 13 | 37 | 52 | 72 | 545 | 0 | 2 | 5 | 11 | 48 |
| Studies with up to six authors | 12 | 30 | 43 | 69 | 545 | 0 | 3 | 7 | 12 | 33 |
| Studies with more than six authors | 13 | 33 | 51 | 74 | 425 | 0 | 2 | 5 | 10 | 105 |
| Studies with less than 32 patients | 12 | 22 | 26 | 29 | 31 | 0 | 2 | 4 | 9 | 58 |
| Studies with at least 32 patients | 32 | 41 | 60 | 84 | 545 | 0 | 2 | 6 | 13 | 105 |
| Studies with up to 80 patients | 12 | 30 | 40 | 59 | 80 | 0 | 2 | 5 | 10 | 58 |
| Studies with magnets up to 1.5T | 12 | 34 | 52 | 78 | 545 | 0 | 2 | 6 | 10 | 105 |
| Studies with magnets stronger than 1.5T | 16 | 29 | 38 | 59 | 221 | 0 | 2 | 6 | 13 | 58 |
| Studies with slices of 1.5 mm or more | 13 | 35 | 57 | 77 | 425 | 0 | 2 | 6 | 10 | 105 |
| Studies with slices inferior to 1.5 mm | 12 | 30 | 40 | 70 | 545 | 0 | 2 | 6 | 13 | 58 |
| Studies employing SPM in pre‐processing | 12 | 32 | 45 | 72 | 545 | 0 | 2 | 6 | 12 | 105 |
| Studies not employing SPM in pre‐processing | 24 | 41 | 63 | 87 | 317 | 0 | 2 | 7 | 10 | 27 |
| Studies with 8 mm smoothing or less | 15 | 33 | 48 | 72 | 425 | 0 | 2 | 5 | 12 | 58 |
| Studies with more than 8 mm smoothing | 12 | 30 | 45 | 75 | 545 | 0 | 2 | 6 | 11 | 105 |
| Studies employing SPM in statistics | 12 | 32 | 45 | 72 | 545 | 0 | 2 | 6 | 12 | 105 |
| Studies not employing SPM in statistics | 24 | 37 | 61 | 83 | 317 | 0 | 2 | 7 | 10 | 27 |
| Studies thresholding at | 15 | 30 | 39 | 56 | 425 | 0 | 4 | 7 | 14 | 48 |
| Studies thresholding at | 12 | 33 | 49 | 72 | 382 | 0 | 2 | 5 | 10 | 105 |
| Studies thresholding at | 16 | 36 | 50 | 64 | 188 | 0 | 2 | 6 | 12 | 58 |
| Studies thresholding at | 13 | 36 | 59 | 90 | 382 | 0 | 2 | 4 | 8 | 105 |
| Studies not employing SVC | 12 | 32 | 47 | 71 | 545 | 2 | 6 | 12 | 105 | |
| Studies employing SVC | 20 | 40 | 71 | 123 | 317 | 2 | 3 | 7 | 27 | |
| (b) All meta‐analyses | 149 | 322 | 534 | 1042 | 4087 | 0 | 2 | 3 | 5 | 24 |
| Meta‐analyses with less than 10 studies | 149 | 259 | 343 | 446 | 952 | 0 | 2 | 5 | 7 | 24 |
| Meta‐analyses with at least 10 studies | 483 | 873 | 1247 | 1652 | 4087 | 0 | 1 | 3 | 4 | 23 |
Relationship between sample size and number of reported foci in subgroups defined by different moderator factors: (a) analyses at the level of single studies and (b) analyses at the level of VBM meta‐analyses
| Zero‐inflated Poisson regression | Meta‐analytic Poisson regression | Pearson correlation | Spearman correlation | Meta‐analytic correlation | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of studies | Estimate |
| Estimate |
|
|
| Rho |
|
|
| |
| (a) All studies | 324 | 1.935% | <0.001 | 2.121% | <0.001 | 0.148 | 0.004 | 0.139 | 0.006 | 0.110 | 0.005 |
| Studies of psychiatric disorders | 215 | 2.420% | <0.001 | 2.165% | <0.001 | 0.205 | 0.001 | 0.115 | 0.047 | 0.107 | 0.012 |
| Studies of neurological disorders | 109 | 1.458% | <0.001 | 1.888% | <0.001 | 0.111 | 0.126 | 0.246 | 0.005 | 0.126 | 0.113 |
| Studies of non‐affective psychosis | 98 | 3.154% | <0.001 | 3.319% | <0.001 | 0.405 | <0.001 | 0.284 | 0.002 | 0.339 | <0.001 |
| Studies of dementia | 58 | 1.076% | 0.004 | 1.749% | <0.001 | 0.089 | 0.253 | 0.305 | 0.010 | 0.122 | 0.174 |
| Studies of neurological diseases other than dementia | 51 | 8.341% | <0.001 | 4.191% | 0.025 | 0.227 | 0.054 | 0.194 | 0.087 | 0.133 | 0.223 |
| Studies of anxiety disorders | 29 | 7.376% | <0.001 | 7.220% | <0.001 | 0.244 | 0.101 | 0.227 | 0.118 | 0.330 | 0.003 |
| Studies of autism | 27 | −9.535% | 0.994 | −11.034% | >0.999 | −0.159 | 0.785 | −0.061 | 0.620 | −0.187 | 0.928 |
| Studies of bipolar disorder | 24 | −8.088% | 0.999 | −10.036% | >0.999 | −0.276 | 0.904 | −0.274 | 0.902 | −0.305 | 0.987 |
| Studies of depressive disorders | 23 | −2.563% | 0.987 | −1.634% | >0.999 | −0.109 | 0.690 | −0.127 | 0.718 | −0.151 | 0.918 |
| Studies of ADHD | 14 | 1.975% | 0.413 | −17.923% | >0.999 | −0.382 | 0.911 | −0.408 | 0.926 | −0.408 | 0.949 |
| Studies published up to 2008 | 202 | 2.939% | <0.001 | 0.217 | 0.001 | 0.179 | 0.005 | ||||
| Studies published after 2008 | 122 | 0.225% | 0.313 | 0.041 | 0.326 | 0.144 | 0.056 | ||||
| Studies up to six authors | 108 | 0.615% | 0.089 | 0.066 | 0.249 | 0.085 | 0.191 | ||||
| Studies with more than six authors | 214 | 2.592% | <0.001 | 0.175 | 0.005 | 0.161 | 0.009 | ||||
| Studies with less than 32 patients | 75 | 52.494% | <0.001 | 0.222 | 0.028 | 0.282 | 0.007 | ||||
| Studies with at least 32 patients | 249 | 1.749% | <0.001 | 0.146 | 0.011 | 0.113 | 0.037 | ||||
| Studies with up to 80 patients | 257 | 5.103% | <0.001 | 0.078 | 0.106 | 0.110 | 0.039 | ||||
| Studies with magnets up to 1.5T | 257 | 2.038% | <0.001 | 0.158 | 0.005 | 0.114 | 0.034 | ||||
| Studies with magnets stronger than 1.5T | 60 | 1.266% | 0.103 | 0.112 | 0.197 | 0.233 | 0.037 | ||||
| Studies with slices of 1.5 mm or more | 161 | 2.935% | <0.001 | 0.207 | 0.004 | 0.175 | 0.013 | ||||
| Studies with slices inferior to 1.5 mm | 151 | 0.850% | 0.010 | 0.074 | 0.183 | 0.083 | 0.156 | ||||
| Studies employing SPM in pre‐processing | 282 | 1.639% | <0.001 | 0.131 | 0.014 | 0.151 | 0.006 | ||||
| Studies not employing SPM in pre‐processing | 29 | 4.943% | <0.001 | 0.510 | 0.002 | 0.255 | 0.091 | ||||
| Studies with 8 mm smoothing or less | 147 | 1.746% | <0.001 | 0.102 | 0.110 | 0.055 | 0.256 | ||||
| Studies with more than 8 mm smoothing | 152 | 1.865% | <0.001 | 0.161 | 0.024 | 0.189 | 0.010 | ||||
| Studies employing SPM in statistics | 281 | 1.622% | <0.001 | 0.130 | 0.015 | 0.150 | 0.006 | ||||
| Studies not employing SPM in statistics | 30 | 5.142% | <0.001 | 0.529 | 0.001 | 0.283 | 0.065 | ||||
| Studies thresholding at | 67 | 1.270% | 0.017 | 0.129 | 0.149 | 0.242 | 0.024 | ||||
| Studies thresholding at | 182 | 2.464% | <0.001 | 0.150 | 0.022 | 0.078 | 0.147 | ||||
| Studies thresholding at | 60 | −2.760% | 0.923 | −0.135 | 0.847 | −0.115 | 0.808 | ||||
| Studies thresholding at | 49 | 2.253% | <0.001 | 0.204 | 0.080 | 0.382 | 0.003 | ||||
| Studies not employing SVC | 296 | 1.877% | <0.001 | 0.145 | 0.072 | 0.165 | 0.002 | ||||
| Studies employing SVC | 26 | 5.693% | <0.001 | 0.479 | 0.007 | −0.130 | 0.263 | ||||
Meta‐analytical combination of the Poisson regressions or the (Fisher‐transformed) correlations separately estimated per each published meta‐analysis.
Increase in the number of reported foci per each increase of 10 patients.
P values were obtained from one‐tailed tests.
Figure 4Relationship between sample size and identified number of foci with abnormalities.
Figure 5Relationship between number of authors and number of identified foci.
Figure 6Relationship between sample size and number of identified foci in studies using FDR correction for multiple comparisons and those using FWE correction for multiple comparisons. Difference in regression slope P = 0.005.
Figure 7Relationship between sample size and number of identified foci in all meta‐analyses (above), meta‐analyses with at least 10 studies (bottom left) and meta‐analyses with less than 10 studies (bottom right).